Pieris Pharmaceuticals announces 1-for-80 reverse stock split

Pieris Pharmaceuticals announced that its Board of Directors has approved a 1-for-80 reverse stock split of the company’s common stock, par value 0.1c, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The company’s common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the company’s existing trading symbol “PIRS“. The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the company’s common stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 720795202. The company filed a Certificate of Change with the Nevada Secretary of State on April 18, 2024 to effect the reverse split.